Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477. doi: 10.1212/NXI.0000000000000477. eCollection 2018 Sep.

2.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.

3.

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.

Mult Scler Relat Disord. 2016 Nov;10:204-212. doi: 10.1016/j.msard.2016.10.010. Epub 2016 Nov 3.

4.

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP.

Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10.

5.

Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.

Rasouli J, Ciric B, Imitola J, Gonnella P, Hwang D, Mahajan K, Mari ER, Safavi F, Leist TP, Zhang GX, Rostami A.

J Immunol. 2015 Jun 1;194(11):5085-93. doi: 10.4049/jimmunol.1403243. Epub 2015 Apr 27.

6.

Assessing the Comparative Outcomes from Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of "Number Needed to Treat" Analysis.

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Leist TP.

Value Health. 2014 Nov;17(7):A392. doi: 10.1016/j.jval.2014.08.864. Epub 2014 Oct 26. No abstract available.

7.

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group.

Lancet Neurol. 2014 Mar;13(3):257-67. doi: 10.1016/S1474-4422(14)70005-5. Epub 2014 Feb 4.

PMID:
24502830
8.

Cladribine: mode of action and implications for treatment of multiple sclerosis.

Leist TP, Weissert R.

Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35. doi: 10.1097/WNF.0b013e318204cd90. Review.

PMID:
21242742
9.

Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics.

Leist TP, Marks S.

Neurology. 2010 Jan 5;74 Suppl 1:S54-61. doi: 10.1212/WNL.0b013e3181c98011.

PMID:
20038764
10.
11.

Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction.

Techavipoo U, Okai AF, Lackey J, Shi J, Dresner MA, Leist TP, Lai S.

J Magn Reson Imaging. 2009 Oct;30(4):699-707. doi: 10.1002/jmri.21836.

PMID:
19787713
12.

When metals compete: a case of copper-deficiency myeloneuropathy and anemia.

Spain RI, Leist TP, De Sousa EA.

Nat Clin Pract Neurol. 2009 Feb;5(2):106-11. doi: 10.1038/ncpneuro1008.

PMID:
19194390
13.
14.

A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.

Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T; Multiple Sclerosis Investigators.

Curr Med Res Opin. 2006 Sep;22(9):1671-8.

PMID:
16968570
15.

Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica?

Okai AF, Muppidi S, Bagla R, Leist TP.

Neurol Res. 2006 Apr;28(3):354-9.

PMID:
16687065
16.

Clinical-magnetic resonance imaging correlations in multiple sclerosis.

Zivadinov R, Leist TP.

J Neuroimaging. 2005;15(4 Suppl):10S-21S. Review.

PMID:
16385015
17.

Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease.

Oh U, Yamano Y, Mora CA, Ohayon J, Bagnato F, Butman JA, Dambrosia J, Leist TP, McFarland H, Jacobson S.

Ann Neurol. 2005 Apr;57(4):526-34.

PMID:
15786444
18.

Involvement of beta-chemokines in the development of inflammatory demyelination.

Banisor I, Leist TP, Kalman B.

J Neuroinflammation. 2005 Feb 24;2(1):7.

19.

Genetic variants of Complex I in multiple sclerosis.

Vyshkina T, Banisor I, Shugart YY, Leist TP, Kalman B.

J Neurol Sci. 2005 Jan 15;228(1):55-64.

PMID:
15607211
20.

CD45 (PTPRC) as a candidate gene in multiple sclerosis.

Vyshkina T, Leist TP, Shugart YY, Kalman B.

Mult Scler. 2004 Dec;10(6):614-7.

PMID:
15584483
21.

Association of haplotypes in the beta-chemokine locus with multiple sclerosis.

Vyshkina T, Shugart YY, Birnbaum G, Leist TP, Kalman B.

Eur J Hum Genet. 2005 Feb;13(2):240-7.

22.

Familial multiple sclerosis and other inherited disorders of the white matter.

Kalman B, Leist TP.

Neurologist. 2004 Jul;10(4):201-15. Review.

PMID:
15245586
23.

A mitochondrial component of neurodegeneration in multiple sclerosis.

Kalman B, Leist TP.

Neuromolecular Med. 2003;3(3):147-58. Review.

PMID:
12835510
24.

Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.

Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA, McFarland HF.

Neurology. 2003 Jun 10;60(11):1849-51.

PMID:
12796549
25.

Genetics of multiple sclerosis: determinants of autoimmunity and neurodegeneration.

Kalman B, Albert RH, Leist TP.

Autoimmunity. 2002 Jul;35(4):225-34. Review.

PMID:
12482189
26.

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.

Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA.

Mult Scler. 2001 Feb;7(1):49-58.

PMID:
11321194
27.

Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis.

Leist TP, Gobbini MI, Frank JA, McFarland HF.

Arch Neurol. 2001 Jan;58(1):57-60.

PMID:
11176937
29.

Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients.

Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S.

Ann Neurol. 2000 Mar;47(3):306-13.

PMID:
10716249
30.

HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease.

Soldan SS, Graf MD, Waziri A, Flerlage AN, Robinson SM, Kawanishi T, Leist TP, Lehky TJ, Levin MC, Jacobson S.

J Infect Dis. 1999 Sep;180(3):685-94.

PMID:
10438355
31.

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.

Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS, Leist TP, Xavier A, White JD, Brown M, Fleisher TA, Top LE, Light S, McFarland HF, Waldmann TA, Jacobson S.

Ann Neurol. 1998 Dec;44(6):942-7.

PMID:
9851439
32.

Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients.

Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP.

Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7568-73.

33.

Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure.

Odermatt B, Eppler M, Leist TP, Hengartner H, Zinkernagel RM.

Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8252-6.

34.

Evidence for a role of IFN gamma in control of Listeria monocytogenes in T cell deficient mice.

Leist TP, Meager A, Exley T, Zinkernagel RM.

Experientia. 1991 Jun 15;47(6):630-2.

PMID:
1829687
35.

Absence of effects of thymopentin on murine host resistance to Listeria monocytogenes.

Rüttner B, Hauser T, Leist TP, Zinkernagel RM.

Thymus. 1991 Feb;17(1):1-10.

PMID:
1901674
36.
37.
38.

Effects of treatment with IL-2 receptor specific monoclonal antibody in mice.

Leist TP, Zinkernagel RM.

J Immunol. 1990 Apr 1;144(7):2847. No abstract available.

PMID:
2108217
40.

Role of tumor necrosis factor in Listeria resistance of nude mice.

Hauser T, Frei K, Zinkernagel RM, Leist TP.

Med Microbiol Immunol. 1990;179(2):95-104.

PMID:
2113160
42.

Latent infections in spinal ganglia with thymidine kinase-deficient herpes simplex virus.

Leist TP, Sandri-Goldin RM, Stevens JG.

J Virol. 1989 Nov;63(11):4976-8.

45.

On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases.

Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A.

Eur J Immunol. 1989 Apr;19(4):689-94.

PMID:
2543584
46.

On the production of immunoglobulins in the central nervous system: an involvement of B cell stimulatory factor 2/interleukin 6 produced intrathecally?

Fontana A, Frei K, Malipiero UV, Leist TP, Schwab M.

Schweiz Arch Neurol Psychiatr (1985). 1989;140(1):38-9. No abstract available.

PMID:
2467367
49.
50.

Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells.

Leist TP, Rüedi E, Zinkernagel RM.

J Exp Med. 1988 May 1;167(5):1749-54.

Supplemental Content

Loading ...
Support Center